These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22607901)

  • 1. Can we defeat meningococcal disease in low and middle income countries?
    Greenwood B; Chiarot E; MacLennan CA; O'Ryan M
    Vaccine; 2012 May; 30 Suppl 2():B63-6. PubMed ID: 22607901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and opportunities for meningococcal vaccination in the developing world.
    Shaker R; Fayad D; Dbaibo G
    Hum Vaccin Immunother; 2018 May; 14(5):1084-1097. PubMed ID: 29393729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
    Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
    Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for controlling invasive meningococcal disease in high income countries.
    Holst J; Nøkleby H; Bettinger JA
    Vaccine; 2012 May; 30 Suppl 2():B57-62. PubMed ID: 22607900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease.
    Harrison LH; Pelton SI; Wilder-Smith A; Holst J; Safadi MA; Vazquez JA; Taha MK; LaForce FM; von Gottberg A; Borrow R; Plotkin SA
    Vaccine; 2011 Apr; 29(18):3363-71. PubMed ID: 21376800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine evaluation: lessons from a meningococcal B vaccine.
    Sarfatti A; Martinón-Torres F; Nadel S
    Arch Dis Child; 2015 Jun; 100(6):514-6. PubMed ID: 25670403
    [No Abstract]   [Full Text] [Related]  

  • 10. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.
    Sáfadi MA; McIntosh ED
    Expert Rev Vaccines; 2011 Dec; 10(12):1717-30. PubMed ID: 22085175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing protection against meningococcal disease.
    Reisinger KS; Black S; Stoddard JJ
    Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing and dynamic epidemiology of meningococcal disease.
    Halperin SA; Bettinger JA; Greenwood B; Harrison LH; Jelfs J; Ladhani SN; McIntyre P; Ramsay ME; Sáfadi MA
    Vaccine; 2012 May; 30 Suppl 2():B26-36. PubMed ID: 22178525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada.
    Huang L; Mauskopf J; Farkouh R; Masaquel C
    Expert Rev Vaccines; 2021 Jan; 20(1):59-72. PubMed ID: 33455487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.